| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
TFMB-(R)-2-HG targets the same pathways as (R)-2-hydroxyglutarate, including inhibition of α-ketoglutarate-dependent dioxygenases such as histone demethylases and DNA demethylases (TET enzymes). By mimicking (R)-2-HG, the compound modulates epigenetic regulation and cellular metabolism. The specific target and mechanism are described in the primary literature.
|
|---|---|
| ln Vitro |
In vitro activity of TFMB-(R)-2-HG is characterized by its effects on α-ketoglutarate-dependent dioxygenases and cellular metabolism. The compound's potency in inhibiting histone demethylases and TET enzymes is assessed in biochemical assays. Detailed in vitro activity data are available in the primary research literature.
|
| ln Vivo |
In vivo activity of TFMB-(R)-2-HG is evaluated in animal models of cancer and other diseases involving (R)-2-HG accumulation. The compound's effects on tumor growth, epigenetic regulation, and metabolic pathways are assessed. Detailed in vivo efficacy data are available in the primary research literature.
|
| Enzyme Assay |
In vitro enzyme assays for TFMB-(R)-2-HG measure its inhibition of α-ketoglutarate-dependent dioxygenases, including histone demethylases (e.g., KDM4, KDM5) and TET enzymes. The enzyme is incubated with its substrate and α-ketoglutarate in the presence of varying concentrations of the compound. Enzyme activity is measured by detecting demethylation or oxidation products. Detailed assay protocols are described in the primary literature.
|
| Cell Assay |
In vitro cell-based assays for TFMB-(R)-2-HG assess its effects on cellular metabolism, epigenetics, and gene expression. Cells are treated with the compound, and effects on histone methylation, DNA methylation, and gene expression are measured by Western blotting, LC-MS/MS, or RNA sequencing. Cell viability and proliferation are also assessed. Detailed cell-based assay protocols are described in the primary literature.
|
| Animal Protocol |
In vivo animal models for TFMB-(R)-2-HG include mouse models of IDH-mutant cancers. The compound is administered to tumor-bearing animals, and its effects on tumor growth, epigenetic markers, and survival are evaluated. Pharmacodynamic studies measure target engagement and pathway modulation. Detailed in vivo protocols are described in the primary literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of TFMB-(R)-2-HG are described in the primary research literature. As a small-molecule analog of (R)-2-HG, its absorption, distribution, metabolism, and excretion are characterized in preclinical studies. Researchers should consult the relevant publications for detailed pharmacokinetic information.
|
| Toxicity/Toxicokinetics |
Toxicity data for TFMB-(R)-2-HG are available from preclinical safety studies. As a research compound, its safety profile is evaluated in standard toxicology studies. Researchers should consult the relevant publications for detailed toxicity information.
|
| Additional Infomation |
TFMB-(R)-2-HG (CAS 1445700-01-5) is a research compound used to study the role of (R)-2-hydroxyglutarate in cancer metabolism and epigenetics. The compound is intended for research use only and is not approved for clinical use. Detailed information on its chemical properties, biological activities, and research applications is available in the primary literature.
|
| Molecular Formula |
C13H11F3O4
|
|---|---|
| Molecular Weight |
288.22
|
| Exact Mass |
288.06
|
| CAS # |
1445700-01-5
|
| Related CAS # |
TFMB-(S)-2-HG;1445703-64-9
|
| PubChem CID |
91885414
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
376.3±42.0 °C at 760 mmHg
|
| Flash Point |
175.2±22.8 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.494
|
| LogP |
1.14
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
380
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C(=O)CC[C@@H]1C(OCC1=CC=CC(C(F)(F)F)=C1)=O
|
| InChi Key |
UXTLNUGKDZMPTC-SNVBAGLBSA-N
|
| InChi Code |
InChI=1S/C13H11F3O4/c14-13(15,16)9-3-1-2-8(6-9)7-19-12(18)10-4-5-11(17)20-10/h1-3,6,10H,4-5,7H2/t10-/m1/s1
|
| Chemical Name |
[3-(trifluoromethyl)phenyl]methyl (2R)-5-oxooxolane-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 250 mg/mL (~867.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4696 mL | 17.3479 mL | 34.6957 mL | |
| 5 mM | 0.6939 mL | 3.4696 mL | 6.9391 mL | |
| 10 mM | 0.3470 mL | 1.7348 mL | 3.4696 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
